Compare ACEL & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACEL | NEO |
|---|---|---|
| Founded | 2009 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 942.7M | 1.0B |
| IPO Year | 2017 | 2008 |
| Metric | ACEL | NEO |
|---|---|---|
| Price | $11.99 | $8.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $14.67 | $11.14 |
| AVG Volume (30 Days) | 285.8K | ★ 1.4M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.34 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.07 | $10.63 |
| Revenue Next Year | $2.81 | $9.73 |
| P/E Ratio | $19.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.55 | $4.72 |
| 52 Week High | $13.31 | $13.74 |
| Indicator | ACEL | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 64.89 | 51.59 |
| Support Level | $10.85 | $7.33 |
| Resistance Level | $12.92 | $8.89 |
| Average True Range (ATR) | 0.24 | 0.45 |
| MACD | 0.09 | 0.17 |
| Stochastic Oscillator | 93.52 | 81.79 |
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, taverns, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.